Comparative Pharmacology
Head-to-head clinical analysis: GABAPENTIN ENACARBIL versus QUDEXY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABAPENTIN ENACARBIL versus QUDEXY XR.
GABAPENTIN ENACARBIL vs QUDEXY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gabapentin enacarbil is a prodrug of gabapentin. It binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P. This modulates neuronal excitability and pain transmission.
Stabilizes neuronal membranes and inhibits repetitive firing of action potentials via blockade of voltage-gated sodium channels; also enhances GABAergic activity and inhibits glutamate release.
Initial: 600 mg orally once daily; titrate to 600 mg three times daily; max 2400 mg/day divided three times daily.
Initial dose 25 mg orally twice daily; titrate by 25-50 mg/day every 1-2 weeks to target dose of 200-400 mg/day in two divided doses. Maximum 400 mg/day.
None Documented
None Documented
Clinical Note
moderateGabapentin enacarbil + Venlafaxine
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Venlafaxine."
Clinical Note
moderateGabapentin enacarbil + Nefazodone
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Nefazodone."
Clinical Note
moderateGabapentin enacarbil + Stiripentol
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Stiripentol."
Clinical Note
moderateTerminal half-life of gabapentin: 5–7 hours in patients with normal renal function. Renal impairment prolongs half-life proportionally to creatinine clearance decline.
Terminal elimination half-life is approximately 70-90 hours after multiple dosing, supporting twice-daily dosing; requires slow titration to steady state (2-3 weeks).
Renal: 100% as unchanged gabapentin (prodrug is rapidly hydrolyzed to gabapentin after absorption). No biliary or fecal elimination of active drug.
Renal: approximately 70% as unchanged drug; fecal: approximately 20%; biliary: minor (<5%).
Category A/B
Category C
Anticonvulsant
Anticonvulsant
Gabapentin enacarbil + Pomalidomide
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Pomalidomide."